MorphoSys (MOR)
(Delayed Data from NSDQ)
$18.55 USD
-0.25 (-1.33%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $18.61 +0.06 (0.32%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MOR 18.55 -0.25(-1.33%)
Will MOR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MOR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MOR
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
MOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) to Undertake Job Cuts in Development Department
Other News for MOR
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
Novartis AG Takes Major Stake in MorphoSys
IN BRIEF: Novartis to squeeze-out remaining MorphoSys shareholders
MorphoSys and Novartis sign delisting agreement
Novartis Aims for Full Acquisition of MorphoSys